From NASH to MASH: Current Market Dynamics in Hepatology
Back Bay Life Science Report · Jonathan P. Gertler, MD and Peter Bak, PhD
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.
The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”
Other topics in this podcast include:
- Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay
- How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market
- Payer monographs and what’s required for hepatology drugs
- The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization
- Which companies are active in the rare liver disease space and how they differentiate themselves
Thank you for listening. You can find previous episodes of the podcast here.
We’d love to hear from you. Ask questions and submit your feedback.